Sep 14, 2026 06:24AM
Aug 6, 2026 07:33AM
Jun 30, 2026 07:31AM
May 13, 2026 07:16AM
May 8, 2026 08:17AM
May 6, 2026 08:31AM
May 6, 2026 08:26AM InflaRx advances izicopan development for kidney diseases
May 4, 2026 07:31AM
Apr 21, 2026 06:51AM
Mar 30, 2026 07:30AM
Mar 20, 2026 04:14PM
Mar 20, 2026 06:59AM
Jan 8, 2026 08:11AM
Dec 31, 2025 06:37AM Raymond James on Inflarx NV (IFRX): 'analyses of the unblinded Phase 3 dataset for vilobelimab...suggests evidence of a positive trend'
Dec 11, 2025 07:32AM
Dec 3, 2025 06:41AM
Nov 11, 2025 04:26AM
Sep 2, 2025 06:19AM
Jul 11, 2025 04:15PM
May 29, 2025 03:46AM
May 28, 2025 10:35AM Guggenheim Reiterates Buy Rating on Inflarx NV (IFRX)
May 28, 2025 04:55AM
May 13, 2025 04:37PM
Apr 29, 2025 06:32AM
Mar 26, 2025 06:57AM
Feb 13, 2025 04:01PM
Jan 16, 2025 06:54AM
Jan 15, 2025 12:30PM InflaRx N.V. (IFRX) Receives European Commission Approval for GOHIBIC for the Treatment of SARS-CoV-2-Induced ARDS
Dec 23, 2024 07:11AM
Nov 19, 2024 08:07AM
Nov 15, 2024 07:52AM
Sep 26, 2024 06:44AM
Sep 25, 2024 07:31AM
Sep 3, 2024 07:30AM
Aug 8, 2024 07:39AM InflaRx N.V. (IFRX) Misses Q2 EPS by 4c
Jun 24, 2024 08:04AM

451,611 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All